[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypokalemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypokalemia":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,65,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100383878","pharmacokinetics-pharmacodynamics-and-safety-profile-of-understudied-drugs-administered-to-children-per-standard-of-care-pops-100383878",false,"NCT04278404","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","POPS or POP02","Inclusion Criteria:\n\n1. Participant is \\\u003C 21 years of age\n2. Parent\u002F Legal Guardian\u002F Adult Participant can understand the consent process and is willing to provide informed consent\u002FHIPAA:\n3. (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment\n\nExclusion Criteria:\n\n1. Participant has a known pregnancy\n\n   Below exclusion criteria apply only to:\n\n   Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)\n2. Has had intermittent dialysis within previous 24 hours\n3. Has had a kidney transplant within previous 30 days\n4. Has had a liver transplant within previous 1 year\n5. Has had a stem cell transplant within previous 1 year\n6. Has had therapeutic hypothermia within previous 24 hours\n7. Has had plasmapheresis within the previous 24 hours\n8. Has a Ventricular Assist Device\n9. Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study",true,"ALL","0 Years","20 Years",{"count":22,"type":23},5000,"ESTIMATED","OBSERVATIONAL","The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51],"Coronavirus Infection (COVID-19)","Pulmonary Arterial Hypertension","Urinary Tract Infections in Children","Hypertension","Pain","Hyperphosphatemia","Primary Hyperaldosteronism","Edema","Hypokalemia","Heart Failure","Hemophilia","Menorrhagia","Insomnia","Pneumonia","Skin Infection","Arrythmia","Asthma in Children","Bronchopulmonary Dysplasia","Adrenal Insufficiency","Fibrinolysis; Hemorrhage","Attention Deficit Hyperactivity Disorder","Multisystem Inflammatory Syndrome in Children (MIS-C)","Kawasaki Disease","Coagulation Disorder","Down Syndrome","RECRUITING","2026-03-31",{"date":55,"type":56},"2026-04-06","ACTUAL",{"date":58,"type":56},"2020-03-05",{"date":60,"type":23},"2027-07",{"name":62,"class":63},"Duke University","OTHER",51,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":18,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100559857","tissue-sodium-quantification-in-patients-with-primary-aldosteronism-see-sodium-to-treat-100559857","NCT06569589","Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat","Tissue Sodium Quantification in Patients With Primary Aldosteronism","SSTT","Inclusion Criteria:\n\n1. Age 21-70 years, with arterial hypertension or suspected to have primary aldosteronism based on Endocrine Society Guidelines.\n2. Male and female patients older than 21 years.\n3. Willingness to participate and ability to provide informed consent.\n\nExclusion Criteria:\n\n1. Patients with exclusion criteria for the MRI, such as:\n\n   * implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants)\n   * iron-based tattoos\n   * any other pieces of metal or devices that are not MR-Safe anywhere in the body\n   * patients who exhibit noticeable anxiety and\u002For claustrophobia into the MRI scanner\n   * pregnancy\n2. Diagnosis of heart failure NYHA classes III and IV\n3. Impaired renal function with eGFR\\\u003C30 ml\u002Fmin or proteinuria \\> 1 g\u002F24h\n4. Liver disease with cirrhosis (Child-Pugh class C) or hypoalbuminemia\n5. Muscular dystrophies\n6. Patients with active cancer or severe comorbid conditions likely to compromise survival or study participation\n7. Unwillingness or other inability to cooperate","21 Years","70 Years",{"count":76,"type":23},80,"The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+\u002FK+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.",[30,79,35],"Primary Aldosteronism",[81,82,83],"NaMRI","muscle Na+ quantification","K+ supplementation","2025-06-04",{"date":86,"type":56},"2025-06-06",{"date":88,"type":56},"2023-12-27",{"date":90,"type":23},"2026-08-31",{"name":92,"class":63},"Jens Titze",4,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":18,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100572662","phase-4-the-cardioprotective-effects-of-improving-potassium-variability-in-maintenance-hemodialysis-patients-100572662","NCT06736184","the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","A Prospective Multicenter Randomized Controlled Trial on the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n1. Age 18-75 years old;\n2. Maintenance hemodialysis ≥3 months;\n3. Serum potassium ≥5.0mmol\u002FL and ≤8mmol\u002FL before dialysis;\n4. Have independent ability;\n5. Complete clinical baseline data.\n\nExclusion Criteria:\n\n1. Complicated with congenital heart disease, myocardial infarction and other heart diseases that may lead to cardiac dysfunction;\n2. Combined with other serious diseases, such as immune diseases, severe liver and kidney dysfunction;\n3. Unable to cooperate with the researcher due to mental reasons;\n4. If the duration of dialysis is less than 4 hours, severe infection;\n5. Patients with malignant tumors or major mental disorders;\n\n6, except primary cardiomyopathy;\n\n7\\. Severe constipation, intestinal obstruction, etc.\n\n8\\. other investigators considered that enrollment was not recommended.","18 Years","75 Years",{"count":104,"type":23},100,"INTERVENTIONAL",[107],"PHASE4","The management of serum potassium in maintenance hemodialysis（MHD ）patients is one of the hot topics at present. In order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important measure to reduce potassium. This measure effectively reduces serum potassium, but increases the risk of hypokalemia after dialysis, which increases the risk of all-cause death in patients. Hyperkalemia and hypokalemia during and at the end of dialysis are important factors for arrhythmia and death in MHD patients. Due to the intermittent nature of hemodialysis treatment, MHD patients often experience frequent fluctuations in serum potassium, which is a potential risk factor for poor prognosis of MHD patients. Serum potassium variability can better reflect the potassium homeostasis in MHD patients. In addition to hyperkalemia and hypokalemia, serum potassium variability is a potential risk factor affecting the prognosis of MHD patients. At present, there are few studies on the effect of improving serum potassium variability on cardiovascular complications, especially multi-center randomized controlled trials. In this study, sodium zirconium cyclosilicate was used to control hyperkalemia before dialysis and increase potassium concentration in dialysate, so as to reduce the risk of hypokalemia after dialysis, and to verify whether improving serum potassium variability can reduce myocardial injury in hemodialysis patients.",[110,35,111,112],"Chronic Kidney Disease on Hemodialysis","Hyperkalemia","Myocardial Injury",[114,115,116],"maintenance hemodialysis","Potassium Variability","Myocardial injury","NOT_YET_RECRUITING","2024-12-12",{"date":120,"type":56},"2024-12-16",{"date":122,"type":23},"2025-03-01",{"date":124,"type":23},"2026-12-31",{"name":126,"class":63},"Qianfoshan Hospital"]